Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 7/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | MERTK | Q12866 | 2/20 | 0.35 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403453 | 0.86 | BCHE (0.39) | KLK7KLK5BCHEKCNA5NAE1 | |
| SCHEMBL402786 | 0.86 | KLK7 (0.42) | KLK7KLK5BCHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL402975 | 0.85 | KLK7 (0.44) | KLK7KLK5BCHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL402963 | 0.81 | BCHE (0.41) | KLK7KLK5BCHENAE1UBA3 | |
| SCHEMBL14363002 | 0.80 | L3MBTL1 (0.39) | KLK7KLK5BCHEL3MBTL1ACACB | |
| SCHEMBL10045291 | 0.80 | — | — | |
| SCHEMBL403009 | 0.79 | L3MBTL1 (0.38) | KLK7KLK5BCHEL3MBTL1REN | |
| SCHEMBL11937054 | 0.75 | CYP2C9 (0.30) | — | |
| SCHEMBL403118 | 0.75 | CYP2C9 (0.30) | — | |
| SCHEMBL9800003 | 0.73 | L3MBTL1 (0.46) | KLK7KLK5BCHEL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | KLK7 1399/4885KLK5 1277/4885BCHE 1419/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | KLK7 1402/4885KLK5 1250/4885BCHE 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.